Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2023-09-14 00:00:00 ET · period of report 2023-09-12 · accession 0001140361-23-044044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-14 | 2023-09-12 | ROIV | Fitzgerald Meghan | Dir | A - Grant | $0.00 | +8,937 | 10.1K | +776% | $0 |
| D | 2023-09-14 | 2023-09-12 | ROIV | Fitzgerald Meghan | Dir | A - Grant | $0.00 | +13.3K | 13.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-09-12 | A | A | 8,937 | $0.00 | 10,089 | D | — | — | (F1) Reflects an annual award of restricted stock units with respect to Common Shares ("RSUs") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of RSUs is scheduled to vest 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-09-12 | A | A | 13,334 | $0.00 | 13,334 | D | $11.22 · — to 2033-09-11 | 13,334 Common Shares | (F2) Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 12, 2024, subject generally to the reporting person's continuous service through such date. |